A Trial to Evaluate the Safety, Tolerability and Preliminary Efficacy of NCR201 in the Treatment of Subjects With Parkinson's Disease

NCT06978920 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

48

Enrollment

INDUSTRY

Sponsor class

Conditions

Parkinson Disease

Interventions

DRUG: Allogeneic dopaminergic neural precursor cell(NCR201)

Sponsor

Nuwacell Biotechnologies Co., Ltd.